Today announced the initiation of the randomized Phase 3 trial of ponatinib.

ARIAD Pharmaceuticals commences ponatinib Stage 3 trial in diagnosed CML newly ARIAD Pharmaceuticals, Inc . today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult individuals with newly diagnosed chronic myeloid leukemia . The efficacy of ponatinib will end up being assessed compared to imatinib predicated on evaluation of the primary endpoint of major molecular response price at 12 a few months. ARIAD expects to complete patient enrollment in the trial by the finish of 2013.

The ReSTART site features an easy to understand glossary also, to help familiarize a person with one of the most common conditions used by rehabilitation healthcare personnel. In addition, visitors will see links to useful support and resources businesses, and also rehabilitation care planning tools.. ARN announces release of ReSTART online recovery reference for rehabilitation The Association of Rehabilitation Nurses today announced the launch of the brand-new ReSTART online recovery resource for rehabilitation. The ReSTART site provides essential information for those starting the trip of rehabilitation, along with their family members, loved ones, and caretakers. The recovery site was made by rehabilitation nurses who understand the special needs of individuals who experience a major injury, chronic illness, or disability.